Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
SAB Biotherapeutics, Inc. (SABS) had Return on Equity of -10.47% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-22.49M |
|
-- |
|
-- |
|
$23.38M |
|
$-23.38M |
|
$0.89M |
|
$-22.49M |
|
$-22.49M |
|
$-22.49M |
|
$-22.49M |
|
$-22.49M |
|
$-22.49M |
|
$-23.38M |
|
$-22.55M |
|
79.75M |
|
79.75M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$107.94M |
|
$14.23M |
|
$130.27M |
|
$238.21M |
|
$11.71M |
|
$3.04M |
|
$11.72M |
|
$23.43M |
|
$214.78M |
|
$214.78M |
|
$214.78M |
|
83.49M |
|
| Cash Flow Statement Financials | |
$-24.11M |
|
$-70.53M |
|
$92.28M |
|
$10.50M |
|
$8.27M |
|
$-2.24M |
|
$12.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.22 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-26.68M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-10.47% |
-10.47% |
|
-9.44% |
|
-10.33% |
|
$2.57 |
|
$-0.33 |
|
$-0.30 |
|